Dimension scores are derived from public data and fields; weighted into the composite. Reference only.
Cosign AI is a healthcare AI company based in San Francisco, with a product focused on clinical trial recruitment. Through real-time EHR integration, it helps investigators and research sites identify eligible patients at the point of care, aiming to reduce recruitment delays caused by manual chart review, missed screening opportunities, and high screen-failure rates.
Based on the available materials, Cosign AI uses AI language agents / large language models to review patient records and perform preliminary eligibility screening against clinical trial inclusion and exclusion criteria. Its published research covers screening for wet age-related macular degeneration trials: the system was developed and validated on 728 patient records, with a test set of 502 patients achieving 97.1% overall accuracy, 82.5% sensitivity, and 97.6% specificity, with an average assessment time of 167 seconds per patient. The product emphasizes its ability to run across multiple patients and trials simultaneously and fit into busy clinic workflows.
The website does not disclose plans, unit pricing, a free trial, or any free quota; it only provides a Contact Us option, suggesting an enterprise / institutional sales model. On integration, it explicitly mentions only Real-Time EHR Integration and seamless embedding into clinical workflows. It does not specify which EHR systems are supported, whether FHIR/HL7 is used, whether API documentation is available, the expected implementation timeline, or whether deployment is on-premises or cloud-based.
Its strengths are a highly vertical use case and a direct focus on a costly pain point in clinical trial recruitment. It also provides relatively concrete validation data, rather than relying solely on marketing claims. For research sites, the potential value of reducing manual chart review is clear. The limitations are also notable: key healthcare AI concerns such as data privacy, medical compliance, auditability, and access control are not disclosed in the available text. The research error analysis also shows remaining issues, including missing external context, medical reasoning errors, and expert annotation problems. In the future, the system will likely need to incorporate multimodal information such as imaging and undergo continued validation in real-world workflows.
Cosign AI is better suited for pharmaceutical companies, clinical trial sponsors, investigator networks, hospital research centers, and specialty clinics—especially trials with complex patient screening rules or recruitment timelines that are highly sensitive. It is not designed for individual users or lightweight standalone use by ordinary clinics. The available text does not provide information on access from China; network availability, cross-border healthcare data compliance, and payment methods are all unknown. For deployment in China, local EHR integration, medical data export controls, and medical device / software compliance requirements would need to be carefully assessed.
⚠ This review is compiled from public sources and does not constitute a purchase recommendation. Verify all facts on the vendor's official site. Verify on co-sign.ai official site.
co-sign.ai is an United States AI Apps provider. TG4G tracks its product information, an overall rating of 8.0/10, and a China-accessibility score of Limited (proxy recommended). Click "Visit Official Site" to reach co-sign.ai directly.